Loading...

Corcept Therapeutics

DB:HTD
Snowflake Description

Flawless balance sheet and good value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
HTD
DB
$1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
HTD Share Price and Events
7 Day Returns
3.1%
DB:HTD
0.7%
DE Pharmaceuticals
0.2%
DE Market
1 Year Returns
-36.1%
DB:HTD
-29%
DE Pharmaceuticals
-10.9%
DE Market
HTD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Corcept Therapeutics (HTD) 3.1% -3.3% -13.3% -36.1% 89.5% 331.2%
DE Pharmaceuticals 0.7% -4.4% -16% -29% -24.8% 8.2%
DE Market 0.2% -2.5% -2% -10.9% 8.9% 6.3%
1 Year Return vs Industry and Market
  • HTD underperformed the Pharmaceuticals industry which returned -29% over the past year.
  • HTD underperformed the Market in Germany which returned -10.9% over the past year.
Price Volatility
HTD
Industry
5yr Volatility vs Market

HTD Value

 Is Corcept Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Corcept Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Corcept Therapeutics.

DB:HTD Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:HTD
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.64 (1 + (1- 21%) (0.13%))
0.759
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.8 * 5.96%)
5%

Discounted Cash Flow Calculation for DB:HTD using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Corcept Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:HTD DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5%)
2019 119.05 Est @ 14.07% 113.39
2020 130.86 Est @ 9.92% 118.70
2021 140.03 Est @ 7.01% 120.98
2022 147.00 Est @ 4.98% 120.95
2023 152.22 Est @ 3.55% 119.29
2024 156.11 Est @ 2.55% 116.52
2025 159.00 Est @ 1.86% 113.03
2026 161.18 Est @ 1.37% 109.13
2027 162.83 Est @ 1.03% 105.00
2028 164.11 Est @ 0.79% 100.79
Present value of next 10 years cash flows $1,137.77
DB:HTD DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $164.11 × (1 + 0.23%) ÷ (5% – 0.23%)
$3,449.83
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $3,449.83 ÷ (1 + 5%)10
$2,118.71
DB:HTD Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,137.77 + $2,118.71
$3,256.48
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $3,256.48 / 114.86
$28.35
DB:HTD Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:HTD represents 0.88891x of NasdaqCM:CORT
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88891x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 28.35 x 0.88891
€25.20
Value per share (EUR) From above. €25.20
Current discount Discount to share price of €9.22
= -1 x (€9.22 - €25.20) / €25.20
63.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Corcept Therapeutics is available for.
Intrinsic value
>50%
Share price is €9.22 vs Future cash flow value of €25.2
Current Discount Checks
For Corcept Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Corcept Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Corcept Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Corcept Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Corcept Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:HTD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $0.66
NasdaqCM:CORT Share Price ** NasdaqCM (2019-06-18) in USD $10.37
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 27.59x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Corcept Therapeutics.

DB:HTD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CORT Share Price ÷ EPS (both in USD)

= 10.37 ÷ 0.66

15.69x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Corcept Therapeutics is good value based on earnings compared to the DE Pharmaceuticals industry average.
  • Corcept Therapeutics is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Corcept Therapeutics's expected growth come at a high price?
Raw Data
DB:HTD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 15.69x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-13.1%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 2x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

DB:HTD PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 15.69x ÷ -13.1%

-1.2x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Corcept Therapeutics earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Corcept Therapeutics's assets?
Raw Data
DB:HTD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $2.49
NasdaqCM:CORT Share Price * NasdaqCM (2019-06-18) in USD $10.37
Germany Pharmaceuticals Industry PB Ratio Median Figure of 8 Publicly-Listed Pharmaceuticals Companies 1.76x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.77x
DB:HTD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CORT Share Price ÷ Book Value per Share (both in USD)

= 10.37 ÷ 2.49

4.17x

* Primary Listing of Corcept Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Corcept Therapeutics is overvalued based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess Corcept Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Corcept Therapeutics has a total score of 4/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

HTD Future Performance

 How is Corcept Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-13.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Corcept Therapeutics expected to grow at an attractive rate?
  • Corcept Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Corcept Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • Corcept Therapeutics's revenue growth is positive but not above the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:HTD Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:HTD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -13.1%
DB:HTD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 0%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 17%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 3.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:HTD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:HTD Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 334 91 1
2022-12-31 218 7 1
2021-12-31 272 52 1
2020-12-31 339 127 4
2019-12-31 295 97 4
DB:HTD Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 258 105 76
2018-12-31 251 116 75
2018-09-30 238 119 152
2018-06-30 216 85 148
2018-03-31 189 86 142
2017-12-31 159 61 129
2017-09-30 130 41 35
2017-06-30 109 39 24
2017-03-31 93 25 13
2016-12-31 81 18 8
2016-09-30 72 18 5
2016-06-30 64 10 1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Corcept Therapeutics's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Corcept Therapeutics's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:HTD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Corcept Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:HTD Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.67 0.67 0.67 1.00
2022-12-31 0.05 0.05 0.05 1.00
2021-12-31 0.40 0.40 0.40 1.00
2020-12-31 1.02 1.23 0.86 4.00
2019-12-31 0.80 0.90 0.70 4.00
DB:HTD Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 0.66
2018-12-31 0.65
2018-09-30 1.32
2018-06-30 1.29
2018-03-31 1.25
2017-12-31 1.14
2017-09-30 0.31
2017-06-30 0.22
2017-03-31 0.11
2016-12-31 0.07
2016-09-30 0.04
2016-06-30 0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Corcept Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Corcept Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Corcept Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

HTD Past Performance

  How has Corcept Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Corcept Therapeutics's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Corcept Therapeutics has delivered over 20% year on year earnings growth in the past 5 years.
  • Corcept Therapeutics's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Corcept Therapeutics's 1-year earnings growth is negative, it can't be compared to the DE Pharmaceuticals industry average.
Earnings and Revenue History
Corcept Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Corcept Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:HTD Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 258.42 76.23 87.24 78.44
2018-12-31 251.25 75.41 81.29 75.25
2018-09-30 237.70 151.73 76.52 70.08
2018-06-30 216.01 147.74 71.69 62.92
2018-03-31 189.26 142.19 65.82 50.25
2017-12-31 159.20 129.12 62.42 40.38
2017-09-30 129.73 35.39 57.38 33.23
2017-06-30 108.69 24.22 51.84 28.59
2017-03-31 92.86 12.55 49.85 26.39
2016-12-31 81.32 8.14 45.24 23.84
2016-09-30 72.48 4.50 42.34 21.45
2016-06-30 64.01 1.32 40.70 18.01
2016-03-31 56.25 -1.60 37.93 15.68
2015-12-31 50.29 -6.41 36.95 15.42
2015-09-30 44.33 -11.26 36.13 15.12
2015-06-30 38.35 -16.67 35.94 14.55
2015-03-31 32.25 -22.28 34.56 15.46
2014-12-31 26.55 -31.38 34.92 18.37
2014-09-30 21.65 -38.61 34.39 21.15
2014-06-30 17.00 -43.51 32.47 23.26
2014-03-31 13.05 -47.86 32.66 23.50
2013-12-31 10.36 -46.01 31.24 20.47
2013-09-30 7.62 -46.01 30.21 18.76
2013-06-30 6.04 -43.40 28.72 16.61
2013-03-31 5.02 -39.10 26.31 14.79
2012-12-31 3.31 -38.05 25.41 14.07
2012-09-30 1.93 -36.86 22.21 15.86
2012-06-30 0.88 -35.00 19.73 16.08

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Corcept Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Corcept Therapeutics used its assets more efficiently than the DE Pharmaceuticals industry average last year based on Return on Assets.
  • Corcept Therapeutics has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Corcept Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Corcept Therapeutics has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

HTD Health

 How is Corcept Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Corcept Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Corcept Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Corcept Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Corcept Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Corcept Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Corcept Therapeutics Company Filings, last reported 2 months ago.

DB:HTD Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 285.76 1.52 186.91
2018-12-31 275.88 0.00 206.76
2018-09-30 259.55 0.00 195.19
2018-06-30 243.51 0.00 159.95
2018-03-31 215.23 0.00 125.36
2017-12-31 190.97 0.00 88.74
2017-09-30 86.30 0.00 75.16
2017-06-30 66.15 4.57 66.17
2017-03-31 49.58 10.11 52.77
2016-12-31 41.38 14.66 51.54
2016-09-30 31.25 18.73 47.87
2016-06-30 25.66 22.30 41.79
2016-03-31 20.17 25.04 40.74
2015-12-31 18.50 27.49 40.44
2015-09-30 13.48 29.64 36.45
2015-06-30 11.53 31.43 37.05
2015-03-31 10.57 32.78 37.95
2014-12-31 -3.39 33.89 24.25
2014-09-30 -1.32 34.65 26.78
2014-06-30 3.45 35.03 33.97
2014-03-31 9.37 35.11 43.62
2013-12-31 21.02 35.07 54.88
2013-09-30 30.77 34.64 63.18
2013-06-30 40.37 33.89 72.22
2013-03-31 51.00 32.80 81.46
2012-12-31 61.78 31.68 93.03
2012-09-30 71.65 30.58 101.63
2012-06-30 32.80 0.00 34.90
  • Corcept Therapeutics has no debt.
  • Corcept Therapeutics has no debt compared to 5 years ago when it was 377.3%.
  • Corcept Therapeutics has no debt, it does not need to be covered by operating cash flow.
  • Corcept Therapeutics has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Corcept Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Corcept Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

HTD Dividends

 What is Corcept Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Corcept Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Corcept Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Corcept Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Corcept Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:HTD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Germany Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 3.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:HTD Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Corcept Therapeutics has not reported any payouts.
  • Unable to verify if Corcept Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Corcept Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Corcept Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Corcept Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Corcept Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Corcept Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Corcept Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

HTD Management

 What is the CEO of Corcept Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Joseph Belanoff
COMPENSATION $6,314,617
AGE 61
TENURE AS CEO 20.4 years
CEO Bio

Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and has held various positions in the Department of Psychiatry and Behavioral Sciences at Stanford University since 1992. From 1997 to 2001, he served as Director of Psychopharmacology at the outpatient division of the Palo Alto Veterans Affairs Hospital. Dr. Belanoff has been a Director of Corcept Therapeutics Incorporated since 1999. He serves as Member of Advisory Board at Immusoft Corporation. He also has valuable expertise in business administration, drug discovery, clinical medicine and psychopharmacology. Dr. Belanoff received his B.A. from Amherst College and his M.D. from the Columbia University's College of Physicians & Surgeons.

CEO Compensation
  • Joseph's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
  • Joseph's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Corcept Therapeutics management team in years:

3.2
Average Tenure
56
Average Age
  • The tenure for the Corcept Therapeutics management team is about average.
Management Team

Joseph Belanoff

TITLE
Co-Founder
COMPENSATION
$6M
AGE
61
TENURE
20.4 yrs

Charlie Robb

TITLE
CFO & Secretary
COMPENSATION
$3M
AGE
55
TENURE
7.8 yrs

Sean Maduck

TITLE
Senior Vice President of Commercial
COMPENSATION
$3M
AGE
41
TENURE
3.2 yrs

Chris James

TITLE
Director of Investor Relations

Hazel Hunt

TITLE
Senior Vice President of Research
TENURE
2.3 yrs

Don Laferle

TITLE
Senior Vice President

Andreas Grauer

TITLE
Chief Medical Officer
AGE
57
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Corcept Therapeutics board of directors in years:

20.4
Average Tenure
64
Average Age
  • The average tenure for the Corcept Therapeutics board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Jim Wilson

TITLE
Chairman
COMPENSATION
$759K
AGE
74
TENURE
20.4 yrs

Joseph Belanoff

TITLE
Co-Founder
COMPENSATION
$6M
AGE
61
TENURE
20.4 yrs

Len Baker

TITLE
Director
COMPENSATION
$268K
AGE
75
TENURE
20.4 yrs

David Mahoney

TITLE
Director
COMPENSATION
$273K
AGE
64
TENURE
14.9 yrs

Dan Swisher

TITLE
Independent Director
COMPENSATION
$280K
AGE
55
TENURE
4 yrs

Charles Nemeroff

TITLE
Member of Scientific Advisory Board
AGE
68

Bruce McEwen

TITLE
Member of Scientific Advisory Board

K. Ranga Krishnan

TITLE
Member of Scientific Advisory Board
AGE
62

Ned Kalin

TITLE
Member of Scientific Advisory Board

Florian Holsboer

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
14. Feb 19 Buy George Baker Individual 12. Feb 19 12. Feb 19 100,000 €10.06 €1,006,278
26. Nov 18 Buy George Baker Individual 21. Nov 18 21. Nov 18 100,000 €11.16 €1,116,408
14. Nov 18 Buy George Baker Individual 09. Nov 18 13. Nov 18 200,000 €11.52 €2,294,317
22. Aug 18 Buy George Baker Individual 20. Aug 18 20. Aug 18 35,681 €11.30 €403,181
20. Aug 18 Buy George Baker Individual 16. Aug 18 17. Aug 18 105,792 €11.21 €1,159,105
16. Aug 18 Buy George Baker Individual 14. Aug 18 15. Aug 18 179,686 €11.03 €1,980,330
X
Management checks
We assess Corcept Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Corcept Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

HTD News

Simply Wall St News

HTD Company Info

Description

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clinical trial to treat patients with Cushing’s syndrome; and Abraxane in combination with relacorilant, which is in Phase II clinical trial to treat metastatic ovarian cancer, as well as in Phase I/II clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer; CORT118335 selective cortisol modulator for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Details
Name: Corcept Therapeutics Incorporated
HTD
Exchange: DB
Founded: 1998
$1,063,281,402
114,858,708
Website: http://www.corcept.com
Address: Corcept Therapeutics Incorporated
149 Commonwealth Drive,
Menlo Park,
California, 94025,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CORT Common Stock Nasdaq Capital Market US USD 14. Apr 2004
DB HTD Common Stock Deutsche Boerse AG DE EUR 14. Apr 2004
LSE 0I3Q Common Stock London Stock Exchange GB USD 14. Apr 2004
Number of employees
Current staff
Staff numbers
166
Corcept Therapeutics employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/18 20:33
End of day share price update: 2019/06/18 00:00
Last estimates confirmation: 2019/06/11
Last earnings filing: 2019/05/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.